NCT01937689View on ClinicalTrials.gov

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib

Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01937689 - Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter